ChiCTR2500102252 版本V1.0 版本创建时间2025/05/12 15:26:41 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2500102252 

最近更新日期:

Date of Last Refreshed on:

2025-05-12 15:26:37 

注册时间:

Date of Registration:

2025-05-12 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

数字化高血压全过程自我管理干预对高血压患者服药、运动和饮食健康行为的影响研究

Public title:

A Study on the Effects of Digital Whole-Process Self-Management Intervention on Medication Adherence, Physical Activity, and Dietary Behaviors in Patients with Hypertension

注册题目简写:

English Acronym:

研究课题的正式科学名称:

数字化高血压全过程自我管理干预对高血压患者服药、运动和饮食健康行为的影响研究

Scientific title:

A Study on the Effects of Digital Whole-Process Self-Management Intervention on Medication Adherence, Physical Activity, and Dietary Behaviors in Patients with Hypertension

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张若彤 

研究负责人:

李勇; 杨芊 

Applicant:

Ruotong Zhang 

Study leader:

Yong Li; Qian Yang 

申请注册联系人电话:

Applicant telephone:

+86 159 2418 7342

研究负责人电话:

Study leader's
telephone:

+86 187 5818 1126

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

22318924@zju.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

chianyoung@zju.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

浙江省杭州市西湖区三墩镇余杭塘路866号浙江大学紫金港校区医学院综合楼1012办公室

研究负责人通讯地址:

浙江省杭州市西湖区三墩镇余杭塘路866号浙江大学紫金港校区医学院综合楼906办公室

Applicant address:

Office 1012, Comprehensive Building, Medical College, Zijingang Campus, Zhejiang University, No. 866 Yuhangtang Road, Sandun Town, Xihu District, Hangzhou, Zhejiang

Study leader's address:

Office 906, Comprehensive Building, Medical College, Zijingang Campus, Zhejiang University, No. 866 Yuhangtang Road, Sandun Town, Xihu District, Hangzhou, Zhejiang

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

浙江大学

Applicant's institution:

Zhejiang University

研究负责人所在单位:

杭州市余杭区第一人民医院; 浙江大学

Affiliation of the Leader:

The First People’s Hospital of Yuhang District, Hangzhou; Zhejiang University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-004-03

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

杭州市余杭区第一人民医院伦理委员会

Name of the ethic committee:

Medical Ethics Committee, The First People’s Hospital of Yuhang District, Hangzhou

伦理委员会批准日期:

Date of approved by ethic committee:

2025-05-09 00:00:00

伦理委员会联系人:

严海斌

Contact Name of the ethic committee:

Haibin Yan

伦理委员会联系地址:

杭州市余杭区第一人民医院

Contact Address of the ethic committee:

The First People’s Hospital of Yuhang District, Hangzhou

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 571 8936 6970

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

杭州市余杭区第一人民医院;浙江大学公共卫生学院

Primary sponsor:

The First People’s Hospital of Yuhang District, Hangzhou; School of Public Health, Zhejiang University

研究实施负责(组长)单位地址:

浙江省杭州市西湖区余杭塘路866号

Primary sponsor's address:

866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

浙江省

市(区县):

Country:

China

Province:

Zhejiang

City:

单位(医院):

浙江大学

具体地址:

浙江省杭州市西湖区余杭塘路866号

Institution
hospital:

Zhejiang University

Address:

866 Yuhangtang Road, Xihu District, Hangzhou, Zhejiang, China

经费或物资来源:

国家自然科学基金面上项目

Source(s) of funding:

National Natural Science Foundation, General Project

研究疾病:

原发性高血压  

Target disease:

Essential hypertension

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本研究旨在构建并验证数字化高血压患者自我管理干预模式,以提升患者的健康素养和自我管理能力,优化疾病管理效果。  

Objectives of Study:

The study aims to develop and validate a digital self-management intervention for patients with hypertension, with the goal of enhancing their health literacy and self-management capabilities, thereby improving the effectiveness of disease management.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)既往被医疗机构诊断为原发性高血压且已开始服用降压药的患者。(2)年龄≥18岁,研究对象为成年高血压患者。 (3)线上干预需具备读写能力,可以使用智能手机和微信客户端,以便更好地参与干预。(4)知情同意,自愿参加研究。

Inclusion criteria

(1) Patients previously diagnosed with primary hypertension by a medical institution and currently taking antihypertensive medications. (2) Aged 18 years or older; participants must be adults with hypertension. (3) Possess basic literacy skills and the ability to use a smartphone and the WeChat application to facilitate participation in the online intervention. (4)Provide informed consent and voluntarily agree to participate in the study.

排除标准:

1)未开始服用降压药的患者(2)有心脑血管疾病、肌肉、关节疼痛等严重并发症等运动禁忌症,或者医生建议不能参加运动的 (3)具有精神障碍的患者,无法自主参与健康干预项目

Exclusion criteria:

1) Patients who have not started taking antihypertensive drugs 2) Those with severe complications such as cardiovascular and cerebrovascular diseases, muscle and joint pain, or other contraindications to exercise, or those advised by doctors not to participate in exercise 3) Patients with mental disorders who are unable to independently participate in health intervention programs

研究实施时间:

Study execute time:

From 2025-04-20 00:00:00 To 2026-03-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-05-15 00:00:00 To 2025-09-30 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

172

Group:

intervention group

Sample size:

干预措施:

干预组的患者将接受数字化高血压自我管理干预

干预措施代码:

Intervention:

Patients in the intervention group will receive a digital self-management intervention for hypertension

Intervention code:

组别:

对照组

样本量:

172

Group:

control group

Sample size:

干预措施:

对照组患者接受常规临床诊治和常规高血压管理

干预措施代码:

Intervention:

Patients in the control group will receive routine clinical diagnosis and treatment, along with standard hypertension management practices.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

浙江省 

市(区县):

 

Country:

China

Province:

Zhejiang

City:

单位(医院):

杭州市余杭区第一人民医院 

单位级别:

三级 

Institution
hospital:

The First People’s Hospital of Yuhang District

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

高血压患者自我管理行为

指标类型:

主要指标

Outcome:

hypertension patient self-management behavior

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

服药依从性

指标类型:

次要指标

Outcome:

medication adherence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

高血压知识水平

指标类型:

次要指标

Outcome:

hypertension knowledge level

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

DASH饮食问卷

指标类型:

次要指标

Outcome:

Dietary Approaches to Stop Hypertension Questionnaire

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患方激活

指标类型:

次要指标

Outcome:

patient activation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

医院总体评价

指标类型:

次要指标

Outcome:

general evaluation of hospital

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血压值

指标类型:

次要指标

Outcome:

blood pressure value

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

服药依从性的改变阶段

指标类型:

次要指标

Outcome:

stage of change in medication adherence

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

慢性疾病自我效能

指标类型:

次要指标

Outcome:

The Chronic Disease Self-Efficacy Scales

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 100 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机化过程采用计算机生成的随机数字表进行操作

Randomization Procedure (please state who generates the random number sequence and by what method):

The randomization process was conducted using a computer-generated random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

No

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

发表文章后,邮件联系

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Contact by email after the article is published

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

EDC

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2025-05-12 15:26:37